dermatomyositis Archives - Page 20 of 24

Abstract Number: 2140 • 2017 ACR/ARHP Annual Meeting
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
Lisa G Rider¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Jesse Wilkerson², Abdullah Faiq¹, John McGrath², Hermine I. Brunner³, Bob Goldberg⁴ and Frederick W Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Social and Scientific Systems, Inc., Durham, NC, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴The Myositis Association, Alexandria, VA
Background/Purpose: Myositis is a rare systemic autoimmune disease with suspected environmental and genetic risk factors, but little is known about specific infections and medications that…
Abstract Number: 2141 • 2017 ACR/ARHP Annual Meeting
Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
Hans Prakash¹, Diego Song¹, Daniel Lichy¹, Pranay Rao², Mina Jain³, Joseph Shrader³, Frederick W Miller⁴, Adam Schiffenbauer⁵, Alexander Gorbach¹ and Lisa G Rider⁵, ¹National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, ²National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, bethesda, MD, ³Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁵Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: To assess microvascular structure and function in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM), we have designed and built a mobile, high-resolution…
Abstract Number: 2147 • 2017 ACR/ARHP Annual Meeting
Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing
Alba Azola¹, Tae Chung², Rachel Mulheren², Genevieve Mckeon², Lisa Christopher-Stine³ and Jeffrey Palmer², ¹Physical Medicine and Rehabilitation, Johns Hopkins University, Lutherville, MD, ²Johns Hopkins University, Baltimore, MD, ³Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The prevalence of dysphagia in patients with inflammatory myopathies has been reported to be as high as 60% (1). Aspiration pneumonia is one of…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
Abstract Number: 2158 • 2017 ACR/ARHP Annual Meeting
HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population
Yukie Yamaguchi¹, Masataka Kuwana², Miwa Kanaoka¹, Tomoya Watanabe¹, Naoko Okiyama³, Takahisa Gono², Masanari Kodera⁴, Takeshi Kambara⁵, Yasuhito Hamaguchi⁶, Mariko Seishima⁷, Kazuhiko Takehara⁶, Manabu Fujimoto³ and Michiko Aihara¹, ¹Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Dermatology, University of Tsukuba, Tsukuba, Japan, ⁴Department of Dermatology, Japan Community Health care Organization Chukyo Hospital, Nagoya, Japan, ⁵Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan, ⁶Department of Dermatology, Kanazawa University, Kanazawa, Japan, ⁷Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan
Background/Purpose: Dermatomyositis (DM) is characterized by inflammation of the skin and skeletal muscle, and is occasionally complicated by interstitial lung disease or concomitant malignancy. It…
Abstract Number: 2159 • 2017 ACR/ARHP Annual Meeting
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Majid Zeidi^1,2, Peter B Chansky^1,2 and Victoria P Werth^3,4, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose : The use of complementary and alternative medicine (CAM) has gained popularity in the United States over the last few decades. Herbal supplements have…
Abstract Number: 2164 • 2017 ACR/ARHP Annual Meeting
Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies
Masashi Taniguchi¹, Ran Nakashima¹, Nobuo Kuramoto¹, Kosaku Murakami¹, Motomu Hashimoto², Hajime Yoshifuji¹, Masao Tanaka², Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (Abs), which mainly consists of anti-Jo1, PL-7, PL-12, EJ, OJ and KS, are the most common myositis-specific autoantibodies (MSAs). It has…
Abstract Number: 2165 • 2017 ACR/ARHP Annual Meeting
Easily Obtainable Myositis Autoantibody Panel Predictive Factors
Jason Weiner¹, Ryan Jessee², Amanda M. Eudy³, Robert T. Keenan⁴, Michael Datto⁵ and Lisa Criscione-Schreiber⁶, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Duke University Medical Center, Chapel Hill, NC, ⁴Rheumatology, NYU-HJD, New York, NY, ⁵Department of Pathology, Duke University, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Myositis autoantibodies have diagnostic, therapeutic and prognostic implications, but their utility in clinical practice is unclear. We aimed to describe our institutionÕs ordering practices…
Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Arya Kadakia¹, Amer Khojah², Gabrielle A. Morgan^3,4, Megan L. Curran⁵, Irwin Benuck⁶, Chinag-Ching Huang¹, Dong Xu⁷ and Lauren M. Pachman^8,9, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁴Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatric Rheumatology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Division of Cardiology, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, IL, ⁷Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…
Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting
Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami¹, Yoshitaka Imura¹, Satoshi Serada², Minoru Fujimoto³, Hajime Yoshifuji¹, Koichiro Ohmura⁴, Tetsuji Naka⁵ and Tsuneyo Mimori⁴, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ³Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ⁴Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
Background/Purpose: Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…
Abstract Number: 2328 • 2016 ACR/ARHP Annual Meeting
Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis
Kazuhiro Kurasawa¹, Satoko Arai¹, Yumeko Namiki¹, Ayae Tanaka¹, Ryutaro Yamazaki², Harutsugu Okada¹, Takayoshi Owada¹, Masafumi Arima¹ and Reika Maezawa¹, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan
Background/Purpose: Anti-MDA5 Ab positive dermatomyositis (DM) is a unique subset of inflammatory myopathy characterized by non- or mild muscle weakness, skin manifestation such as…
Abstract Number: 275 • 2016 ACR/ARHP Annual Meeting
In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients
Leandro Ladislau^1,2,3, Xavier Suárez-Calvet^1,4, Claudia Benjamin³, Ségolène Toquet¹, Benjamin Terrier⁵, Flore Rozenberg⁶, Vincent Mouly¹, Gillian Butler Browne⁷, Werner Stenzel⁸, Olivier Benveniste⁹ and Yves Allenbach¹⁰, ¹Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ²Programa de Ciências Biomédicas, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ³Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Neuromuscular Diseases Unit, Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona and Institut de Recerca Sant Pau., Barcelona, Spain, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Departement de Virologie, Hôpital Cochin, Paris Descartes Universités, Paris, France, ⁷Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁸Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: The type I interferons (IFN-I) including IFN-a, and IFN-b are key cytokines involved in innate immune response to viral infection. Almost all cells can…
Abstract Number: 285 • 2016 ACR/ARHP Annual Meeting
Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort
Anne Tebo¹, Troy Jaskowski² and Lisa Peterson¹, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²ARUP Laboratories, Salt Lake City, UT
Background/Purpose: Antibodies to small ubiquitin-like modifier activating enzyme (SAE) are associated with diagnosis of dermatomyositis (DM). The aims of this study were to establish the…
Abstract Number: 286 • 2016 ACR/ARHP Annual Meeting
Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis
Jaehyung Hur¹, Dong Jin Go², Sang Wan Chung³, You Jung Ha³, Eun Ha Kang¹, Jin Kyun Park⁴, Eun Young Lee², Eun Bong Lee², Yeong Wook Song⁴ and Yun Jong Lee⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Recent studies have suggested that neutrophil to lymphocyte ratio (NLR) could be an emerging predictive marker of disease activity or mortality in patients with…
Abstract Number: 1187 • 2016 ACR/ARHP Annual Meeting
Ultraviolet Radiation Exposures Are Associated with Dermatomyositis in a National Myositis Registry
Christine G. Parks¹, Jesse Wilkerson², Kathryn M. Rose², Abdullah Faiq³, Payam Noroozi Farhadi³, Craig S. Long⁴, Nastaran Bayat³, Hermine I. Brunner⁵, Bob Goldberg⁶, John McGrath², Frederick W. Miller³ and Lisa G. Rider³, ¹Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Durham, NC, ²Social and Scientific Systems, Inc., Durham, NC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ⁴NOAA/National Weather Service, National Centers for Environmental Prediction Climate Prediction Center, College Park, MD, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶The Myositis Association, Alexandria, VA
Background/Purpose: Previous studies suggest exposure to ultraviolet (UV) radiation may be a risk factor for dermatomyositis (DM) and autoantibody phenotypes, based on differences in prevalence…

Abstracts tagged "dermatomyositis"

Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry

Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage

Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing

The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

HLA-DRB104:03/04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies

Easily Obtainable Myositis Autoantibody Panel Predictive Factors

Dyslipidemia in Juvenile Dermatomyositis

Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.

Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis

In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients

Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort

Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis

Ultraviolet Radiation Exposures Are Associated with Dermatomyositis in a National Myositis Registry